AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22464118 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy
Number of subjects: 84
Study 22464118 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 84
Study 22464118 — intervention group
Group type: COMPARATOR
Intervention: Standard prenatal care (Control)
Number of subjects: 84
Study 20144174 — intervention group
Group type: EXPERIMENTAL
Intervention: Human placenta extract
Number of subjects: 108
Study 20144174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 17687341 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide LAR combined with TMX (n=56)
Number of subjects: 109
Study 17687341 — intervention group
Group type: COMPARATOR
Intervention: TMX alone (n=53; control group)
Number of subjects: 109
Study 15841811 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive and operative regimen for mothers (n = 15)
Number of subjects: 27
Study 15841811 — intervention group
Group type: COMPARATOR
Intervention: Simple care and advice program for mothers (n = 12)
Number of subjects: 27
Study 10878419 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (2.5 mg/kg once a day)
Number of subjects: 0
Study 10878419 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (1.25 mg/kg twice a day)
Number of subjects: 0
Study 9280744 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent mothers' newborns
Number of subjects: 430
Study 9280744 — intervention group
Group type: COMPARATOR
Intervention: Adult mothers' newborns
Number of subjects: 430
Study 1555424 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosurf (5 ml/kg, intratracheal surfactant preparation)
Number of subjects: 14
Study 1555424 — intervention group
Group type: COMPARATOR
Intervention: Air (5 ml/kg, control group)
Number of subjects: 14
Study 3925478 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.6 mg
Number of subjects: 12
Study 3925478 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 1.2 mg
Number of subjects: 12
Study 3925478 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.0 mg)
Number of subjects: 12
Study 3577645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 0
Study 3577645 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium
Number of subjects: 0
Study 3577645 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubocurarine
Number of subjects: 0
Study 3577645 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 0
Study 3577645 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 0
Study 3577645 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 31978403 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition with retrieval practice
Number of subjects: 82
Study 31978403 — intervention group
Group type: COMPARATOR
Intervention: Condition without retrieval practice
Number of subjects: 82
Study 31978403 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's Disease patients
Number of subjects: 82
Study 31978403 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 82
Study 31978403 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Alzheimer's Disease and healthy controls)
Number of subjects: 82
Study 30910755 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic bone graft
Number of subjects: 57
Study 30910755 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium mesh cage
Number of subjects: 57
Study 30910755 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 57
Study 28699570 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based approaches to vector control (pesticide-free dengue vector control)
Number of subjects: 150
Study 28699570 — intervention group
Group type: COMPARATOR
Intervention: Standard government dengue control (pesticide-dependent approaches)
Number of subjects: 150
Study 25066869 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock wave lithotripsy
Number of subjects: 45
Study 25066869 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde intrarenal surgery
Number of subjects: 45
Study 25066869 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniperc
Number of subjects: 45
Study 24211128 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic repair
Number of subjects: 154
Study 24211128 — intervention group
Group type: COMPARATOR
Intervention: Subacromial decompression
Number of subjects: 154
Study 21166579 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 150
Study 21166579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 18454655 — intervention group
Group type: COMPARATOR
Intervention: SRP + placebo (N = 15)
Number of subjects: 30
Study 18454655 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + doxycycline (100 mg/day for 14 days) (N = 15)
Number of subjects: 30
Study 16927289 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine treatment for longer than 1 year
Number of subjects: 502
Study 12614908 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg levodopa
Number of subjects: 40
Study 12614908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10699690 — intervention group
Group type: COMPARATOR
Intervention: Nd‐YAG laser only
Number of subjects: 29
Study 10699690 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Nd‐YAG laser/HDR brachytherapy
Number of subjects: 29
Study 9061112 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral maxillary nerve block with local anaesthetics (5-10 ml of bupivacaine 0.5% and lignocaine 2%)
Number of subjects: 32
Study 9061112 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral maxillary nerve block with local anaesthetics
Number of subjects: 32
Study 9061112 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nerve block)
Number of subjects: 32
Study 8448063 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg carbamazepine liquid suspension
Number of subjects: 12
Study 8448063 — intervention group
Group type: COMPARATOR
Intervention: Conventional tablet formulation
Number of subjects: 12
Study 8448063 — intervention group
Group type: COMPARATOR
Intervention: Controlled release tablet formulation
Number of subjects: 12
Study 8448063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3492378 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg propyphenazone
Number of subjects: 210
Study 3492378 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg propyphenazone
Number of subjects: 210
Study 3492378 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg acetylsalicylic acid (ASA)
Number of subjects: 210
Study 3492378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 29786165 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot‐PLIF
Number of subjects: 78
Study 29786165 — intervention group
Group type: COMPARATOR
Intervention: Freehand‐PLIF
Number of subjects: 78
Study 27020170 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-EP2006
Number of subjects: 316
Study 27020170 — intervention group
Group type: COMPARATOR
Intervention: Reference pegfilgrastim
Number of subjects: 316
Study 24424705 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to aripiprazole
Number of subjects: 115
Study 24424705 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to ziprasidone
Number of subjects: 115
Study 22441507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clinics (patients monitored by clinician order)
Number of subjects: 176
Study 22441507 — intervention group
Group type: COMPARATOR
Intervention: Random baseline sample
Number of subjects: 176
Study 22441507 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 176
Study 20459349 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% DHEA
Number of subjects: 218
Study 20459349 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% DHEA
Number of subjects: 218
Study 20459349 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% DHEA
Number of subjects: 218
Study 20459349 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo not specified)
Number of subjects: 218
Study 18599271 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid IMF
Number of subjects: 120
Study 18599271 — intervention group
Group type: COMPARATOR
Intervention: Eyelet wire ties (Control)
Number of subjects: 120
Study 16898862 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 oz (84 g) of almonds daily for 4 weeks
Number of subjects: 30
Study 16898862 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 oz (168 g) of almonds daily for 4 weeks
Number of subjects: 30
Study 16898862 — intervention group
Group type: COMPARATOR
Intervention: Control group (no almonds)
Number of subjects: 30
Study 12830407 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 104
Study 12830407 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 104
Study 12830407 — intervention group
Group type: COMPARATOR
Intervention: Protease inhibitors
Number of subjects: 104
Study 12830407 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 104
Study 10802368 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant boost technique (CBT) radiation therapy, 46.8 Gy in 26 fractions with a concomitant boost of 18.2 Gy (0.7 Gy per fraction) to the gross disease, total dose 65 Gy in 26 fractions.
Number of subjects: 97
Study 10802368 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment technique (CTT) radiation therapy, 70.8 Gy in 38 fractions.
Number of subjects: 97
Study 10802368 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant boost technique (CBT) radiation therapy.
Number of subjects: 97
Study 10802368 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment technique (CTT) radiation therapy.
Number of subjects: 97
Study 8623995 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: 75 mg intramuscular diclofenac, 1000 mg intravenous metamizole, 5.3 +/- 1 mg epidural morphine, and 15-20 ml mepivacaine 1% administered 85 +/- 41 min before skin incision. Epidural analgesia maintained by injections of 0.1 ml.kg‐1.h‐1 mepivacaine 1%.
Number of subjects: 142
Study 8623995 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Balanced analgesia regimen before wound closure (221 +/- 86 min after skin incision).
Number of subjects: 142
Study 8623995 — intervention group
Group type: COMPARATOR
Intervention: Group 3: Control group, did not receive any study substances.
Number of subjects: 142
Study 1317828 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 48
Study 1317828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 3912367 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cephradine
Number of subjects: 84
Study 3912367 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal cephradine
Number of subjects: 84
Study 3912367 — intervention group
Group type: EXPERIMENTAL
Intervention: Other antibiotics after cephradine
Number of subjects: 84
Study 30554883 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal growth factor (EGF) applied directly without stripping of the perforation edge; n=26
Number of subjects: 44
Study 30554883 — intervention group
Group type: COMPARATOR
Intervention: Observation only; n=18
Number of subjects: 44
Study 28454806 — intervention group
Group type: EXPERIMENTAL
Intervention: IMR measurement after successful PPCI
Number of subjects: 242
Study 28454806 — intervention group
Group type: EXPERIMENTAL
Intervention: IMR measurement
Number of subjects: 242
Study 27321485 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention model including antituberculosis drugs for at least 3 weeks, accurate wound assessment, complete excision of sinus tract and surrounding devitalized tissue, vacuum sealing drainage (VSD) for 1 to 2 weeks, followed by direct suture or grafting skin or flap.
Number of subjects: 43
Study 27321485 — intervention group
Group type: COMPARATOR
Intervention: Routine dressing change every 3 days after initial antituberculosis drugs for at least 3 weeks.
Number of subjects: 43
Study 27321485 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group
Number of subjects: 43
Study 27321485 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 24911420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Social Skills Training (CBSST)
Number of subjects: 149
Study 24911420 — intervention group
Group type: COMPARATOR
Intervention: Goal-Focused Supportive Contact (GFSC)
Number of subjects: 149
Study 22577180 — intervention group
Group type: EXPERIMENTAL
Intervention: National Exercise Referral Scheme (NERS)
Number of subjects: 2160
Study 22577180 — intervention group
Group type: COMPARATOR
Intervention: Normal care and brief written information
Number of subjects: 2160
Study 19054492 — intervention group
Group type: EXPERIMENTAL
Intervention: Disruption of IS/OS junction
Number of subjects: 101
Study 19054492 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative macular thickness
Number of subjects: 101
Study 19054492 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative macular thickness
Number of subjects: 101
Study 19054492 — intervention group
Group type: EXPERIMENTAL
Intervention: Thickness difference and foveal contour
Number of subjects: 101
Study 17315155 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine (Ara-C) (20 mg twice daily for 10 days)
Number of subjects: 217
Study 17315155 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea with or without all-trans retinoic acid (ATRA)
Number of subjects: 217
Study 15471181 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT) with 2 x 2000 impulses of 0.28 mJ/mm2 at an interval of two weeks
Number of subjects: 43
Study 15471181 — intervention group
Group type: COMPARATOR
Intervention: Control group with 2 x 2000 impulses of < 0.07 mJ/mm2 at an interval of two weeks
Number of subjects: 43
Study 11576096 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 24
Study 11576096 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 24
Study 10021880 — intervention group
Group type: EXPERIMENTAL
Intervention: Children after cardiosurgical correction of ASD II
Number of subjects: 17
Study 10021880 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (control group)
Number of subjects: 17
Study 8147360 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactaid
Number of subjects: 10
Study 8147360 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactrase
Number of subjects: 10
Study 8147360 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy Ease
Number of subjects: 10
Study 8147360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3170089 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation of 20 mg a day
Number of subjects: 89
Study 3170089 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 89
Study 31537225 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual pump blood transfusion filtered by leukocyte depletion filter
Number of subjects: 40
Study 31537225 — intervention group
Group type: COMPARATOR
Intervention: Residual pump blood transfusion without filtration
Number of subjects: 40
Study 28183298 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-free and flavour-free e-liquid vaping for 1 hour
Number of subjects: 0
Study 28183298 — intervention group
Group type: COMPARATOR
Intervention: Placebo (controlled environment)
Number of subjects: 0
Study 25671594 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 14
Study 25671594 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 14
Study 24378322 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 17
Study 24378322 — intervention group
Group type: COMPARATOR
Intervention: Control (non-carriers)
Number of subjects: 17
Study 21960182 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol (0.65 g/kg)
Number of subjects: 20
Study 21960182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19540365 — intervention group
Group type: EXPERIMENTAL
Intervention: Acu-TENS applied over acupuncture points Lieque and Dingchuan for 45 min prior to exercise (Group 1)
Number of subjects: 30
Study 19540365 — intervention group
Group type: EXPERIMENTAL
Intervention: Acu-TENS applied prior to and throughout the exercise test (Group 2)
Number of subjects: 30
Study 19540365 — intervention group
Group type: COMPARATOR
Intervention: No electrical output from the device, mimicking Group 1 (Group 3)
Number of subjects: 30
Study 17466492 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER 3 mg
Number of subjects: 618
Study 17466492 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER 9 mg
Number of subjects: 618
Study 17466492 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER 15 mg
Number of subjects: 618
Study 17466492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 618
Study 15887835 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400mg single oral dose
Number of subjects: 12
Study 12377959 — intervention group
Group type: EXPERIMENTAL
Intervention: EMO group (writing about deepest thoughts and feelings regarding breast cancer)
Number of subjects: 60
Study 12377959 — intervention group
Group type: EXPERIMENTAL
Intervention: POS group (writing about positive thoughts and feelings regarding breast cancer)
Number of subjects: 60
Study 12377959 — intervention group
Group type: COMPARATOR
Intervention: CTL group (writing about facts of their breast cancer experience)
Number of subjects: 60
Study 12377959 — intervention group
Group type: EXPERIMENTAL
Intervention: EMO group and POS group
Number of subjects: 60
Study 10530097 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral-B 3D Plaque Remover
Number of subjects: 44
Study 10530097 — intervention group
Group type: COMPARATOR
Intervention: sonicare electric toothbrush
Number of subjects: 44
Study 9307648 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 50 micrograms/ml latanoprost once daily from day 4 to day 18
Number of subjects: 24
Study 9307648 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops once daily from day 4 to day 18
Number of subjects: 24
Study 2036894 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parathyroidectomy including autotransplantation (PTX + AT)
Number of subjects: 40
Study 2036894 — intervention group
Group type: COMPARATOR
Intervention: Subtotal parathyroidectomy (PTX)
Number of subjects: 40
Study 7294185 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of haloperidol
Number of subjects: 44
Study 7294185 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of haloperidol
Number of subjects: 44
Study 7294185 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of haloperidol
Number of subjects: 44
Study 7294185 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 44
Study 31468106 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength and balance training intervention (2 months, once-weekly home-based)
Number of subjects: 143
Study 27828910 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex‐Press Minishunt
Number of subjects: 41
Study 27828910 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed valve
Number of subjects: 41
Study 27828910 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 41
Study 27828910 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sclerectomy
Number of subjects: 41
Study 25424990 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg atorvastatin daily
Number of subjects: 1152
Study 25424990 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 1152
Study 25954110 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + chemotherapy (AGITG MAX trial)
Number of subjects: 332
Study 25954110 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + chemotherapy (TRACC registry)
Number of subjects: 332
Study 25954110 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (AGITG MAX trial)
Number of subjects: 332
Study 25954110 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (TRACC registry)
Number of subjects: 332
Study 25954110 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + chemotherapy (TRACC registry, patients without peritoneal metastases)
Number of subjects: 332
Study 25954110 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (TRACC registry, patients without peritoneal metastases)
Number of subjects: 332
Study 25954110 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + chemotherapy (MAX trial)
Number of subjects: 332
Study 25954110 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + chemotherapy (TRACC)
Number of subjects: 332
Study 25954110 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + chemotherapy (NSWCC)
Number of subjects: 332
Study 25954110 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy duration
Number of subjects: 332
Study 24255945 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive similarity maps
Number of subjects: 0
Study 24255945 — intervention group
Group type: COMPARATOR
Intervention: Hierarchical clustering approaches
Number of subjects: 0
Study 24255945 — intervention group
Group type: COMPARATOR
Intervention: Hierarchical two-means clustering
Number of subjects: 0
Study 20922535 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet of 5.0 MJ/day for 1 week
Number of subjects: 40
Study 20922535 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet of 5.0 MJ/day for 5 months
Number of subjects: 40
Study 20922535 — intervention group
Group type: COMPARATOR
Intervention: Lean women (control group)
Number of subjects: 40
Study 19036057 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17014595 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg twice daily (BID)
Number of subjects: 449
Study 17014595 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg once daily (QD)
Number of subjects: 449